Safety Assessment of Osthole Isolated from Prangos ferulacea: Acute and Subchronic Toxicities and Modulation of Cytochrome P450

Abstract

Background: Osthole (7-methoxy-8-(3-methyl-2-butenyl)-2H-1-benzopyran-2-one), a natural coumarin derivative, has exhibited various pharmacological properties. In addition, the possibility of its development as a promising lead compound for drug discovery has been proposed. However, there is little toxicological information regarding safety of repeated exposure to this coumarin. Objective: The present study evaluated the potential toxicity of osthole after acute and subchronic administration in rodents. In addition, we investigated the effect of osthole on different hepatic CYP gene expressions in male rats receiving the highest dose of osthole. Methods: In the acute toxicity study, single doses of osthole (100, 500, and 1000 mg/kg) were administered intraperitoneally to mice and the mice were then monitored for 14 days. In the subchronic toxicity study, osthole was administered orally to rats at doses of 5, 25, and 50 mg/kg/day for 45 days. Results:The results of acute study indicated that LD50 of osthole is about 710 mg/kg. There was no significant difference in body weight, relative organ weight, and hematological parameters in the subchronic toxicity study. Biochemical analysis showed some significant changes including in creatinine, potassium, glucose, albumin, and urea levels. The results of histopathological studies showed that all the removed organs, specially kidney, were affected by subchronic exposure to osthole. The change in the kidney included peritubular capillary congestion, hemorrhage in renal parenchyma, mild tubular dilatation, and mild interstitial infiltration of inflammatory cells. Furthermore, osthole treatment caused an induction in CYP1A2, CYP2E1, and CYP2C11. Conclusions: Finally, concerning the common classification of relative toxicity of chemicals, acute toxicity results suggested that osthole is a moderately toxic substance when administered i.p. The obtained data from subchronic study supported the evidence of renal function impairment by osthole. The no-observed adverse-effect level (NOAEL) of the extract for both male and female rats is considered less than 5 mg/kg.

The Nonvolatile and Volatile Metabolites of Prangos ferulacea and Their Biological Properties

“…Investigations of the safety of osthol (5) have found that it is moderately toxic substance when administered i. p. in rodents. The no-observed adverse-effect level of osthol (5) for both male and female rats is considered to be less than 5 mg/kg [43]. These findings suggest that osthol (5) might prove to be useful as a therapeutic agent in carcinoma treatment mainly in phenotypic-resistant cell lines due to defect in p53 function.…”

Safety Profile of Nutraceuticals Rich in Coumarins: An Update

“…In a subchronic study, osthole was administered to Wistar rats in doses of 5–50 mg/kg bw for 45 days, by oral route. The results showed pulmonary hemorrhage and mild inflammatory processes in kidneys and liver of the animals treated with higher doses of osthole ( Shokoohinia et al, 2017 ).…”

Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review

“…Reviewing current literature can help to collect information regarding the bio-efficacy and safety of the administration of significant phytochemicals in the prevention and management of different malignancies and their relevant complications. Since osthol safety has been investigated, the no-observed adverse-effect level (NOAEL) of osthol for both male and female rats is considered to be less than 5 mg/kg [ 93 ]. We suggest to perform randomized, controlled, trials with adequate sample size in order to validate the safety and efficacy of osthol in managing patients with malignancies.…”